STML - Stemline Therapeutics, Inc.
| Previous Close | 9.81 |
| Open | 9.78 |
| Bid | 9.60 x 900 |
| Ask | 13.15 x 1800 |
| Day's Range | 9.78 - 10.39 |
| 52 Week Range | 7.82 - 18.22 |
| Volume | 575,649 |
| Avg. Volume | 629,071 |
| Market Cap | 495.317M |
| Beta (3Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.28 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.11 |
- GlobeNewswire
Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer
NEW YORK, Dec. 06, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire
Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting
NEW YORK, Dec. 06, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire
Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference
NEW YORK, Nov. 29, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- Thomson Reuters StreetEvents
Edited Transcript of STML earnings conference call or presentation 8-Nov-19 1:00pm GMT
Q3 2019 Stemline Therapeutics Inc Earnings Call
- TheStreet.com
Differing Post-Earnings Tales of 2 Small-Cap Underachievers
Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.
- Benzinga
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...
- GlobeNewswire
Stemline Therapeutics Reports Third Quarter 2019 Financial Results
Net revenue for ELZONRIS® was $13.3 million for the third quarterNew patient starts estimated to have increased greater than 20% from last quarterConference call and live.
- GlobeNewswire
Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting
NEW YORK, Nov. 06, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire
Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019
Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and webcast on Friday, November 8, 2019 at 8:00 a.m. ET to report its third quarter 2019 financial results and other business highlights. ELZONRIS® (tagraxofusp-erzs), a CD123-directed cytotoxin, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA).
- Insider Monkey
Stemline Therapeutics Inc (STML) Is Burning These Hedge Funds
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- Simply Wall St.
Did Changing Sentiment Drive Stemline Therapeutics's (NASDAQ:STML) Share Price Down By 41%?
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...
- GlobeNewswire
Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology
NEW YORK, Oct. 08, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress
NEW YORK, Oct. 01, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress
NEW YORK, Sept. 27, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
NEW YORK, Sept. 26, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- Simply Wall St.
Does The Stemline Therapeutics, Inc. (NASDAQ:STML) Share Price Tend To Follow The Market?
If you're interested in Stemline Therapeutics, Inc. (NASDAQ:STML), then you might want to consider its beta (a measure...
- GlobeNewswire
Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference
NEW YORK, Sept. 18, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- Insider Monkey
Mangrove Partners’ Return, AUM, and Holdings
Back in 2010, Nathaniel August, an activist investor, decided it was time to launch his own hedge fund, and he named it Mangrove Partners after a tree species that has the ability to survive extreme weather conditions such as storms and hurricanes. The idea behind this name was to symbolically present hedge fund that is […]
- Thomson Reuters StreetEvents
Edited Transcript of STML earnings conference call or presentation 2-Aug-19 12:00pm GMT
Q2 2019 Stemline Therapeutics Inc Earnings Call
- GuruFocus.com
Stemline Therapeutics Inc (STML) CEO Ivan Bergstein Sold $515,697 of Shares
CEO of Stemline Therapeutics Inc (30-Year Financial, Insider Trades) Ivan Bergstein (insider trades) sold 35,010 shares of STML on 08/14/2019 at an average price of $14.73 a share. Continue reading...
- Simply Wall St.
Should Stemline Therapeutics, Inc. (NASDAQ:STML) Be Your Next Stock Pick?
Stemline Therapeutics, Inc. (NASDAQ:STML) is a company with exceptional fundamental characteristics. Upon building up...
- TheStreet.com
Checking In on 2 Small Biotech Names That Had Big Quarters
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
- GlobeNewswire
Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
NEW YORK, Aug. 09, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire
Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock
NEW YORK, Aug. 08, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and.
- GlobeNewswire
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
NEW YORK, Aug. 07, 2019 -- Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and.
